Market Overview

Gene Therapy For Cystic Fibrosis| A Drug Pipeline Analysis Report 2018| Technavio


Technavio has announced their latest pipeline analysis report on the
drug pipeline for gene
therapy for cystic fibrosis
. The report includes a detailed
analysis of the pipeline molecules under investigation within the
defined data collection period to treat cystic fibrosis.

This press release features multimedia. View the full release here:

Technavio has published a new report on the drug development pipeline for cystic fibrosis, including ...

Technavio has published a new report on the drug development pipeline for cystic fibrosis, including a detailed study of the pipeline molecules. (Graphic: Business Wire)

This report by Technavio
presents a detailed analysis of the market, including regulatory
framework, drug development strategies, recruitment strategies, and key
companies that are expected to play an essential role in the growth of
the market.

This report is available at a USD 1,000 discount for a limited time
market snapshot before purchasing

Cystic fibrosis: Market overview

Cystic fibrosis is a genetic defect characterized by the buildup of
thick, sticky mucus that can damage the lungs. It may also affect other
organs such as liver, intestines, pancreas, and kidneys. This thick
mucus blocks the airways and damages the lungs, which makes it more
prone to bacterial infection. These bacteria multiply and lead to a
serious chronic problem. Cystic fibrosis generally occurs due to a
defect in both the copies of the gene for cystic fibrosis transmembrane
conductance regulator (CFTR) protein.

According to a senior market research analyst at Technavio, "Various
studies have shown that there are over 1,700 types of mutations of the
CFTR gene, each responsible for cystic fibrosis. People with cystic
fibrosis lose a high level of salt through sweat, and the severity of
cystic fibrosis differs from person to person. In some instances, it has
been observed that people with bronchiectasis tend to develop cystic
fibrosis in long-term, which leads to failure of the respiratory system."

Gene therapy for cystic fibrosis: Segmentation

This pipeline analysis report segments the gene therapy for cystic
fibrosis market based on therapies employed (monotherapy), RoA
(intravenous, aerosol inhalation, parenteral, and implant), therapeutic
modality (gene), targets (CFTR gene), MoA (gene therapy), geographical
segmentation (US), and recruitment status (not applicable). It provides
an in-depth analysis of the prominent factors influencing the market,
including drivers, opportunities, trends, and industry-specific

Based on targets, around 67% of the molecules that are being
investigated for the treatment of cystic fibrosis is a CFTR gene. CFTR
gene provides instructions for making a protein called the CFTR. The
functions of CFTR gene includes being a channel across the membrane of
cells that produce mucus, saliva, and sweat.

Looking for more information on this market? Request
a free sample report

Technavio's sample reports are free of charge and contain multiple
sections of the report such as the market size and forecast, drivers,
challenges, trends, and more.

Some of the key topics covered in the report include:

Scope of the Report

Regulatory Framework

Drug Development Landscape

  • Drugs under development
  • Indications coverage

Drug Development Strategies

  • Therapies employed
  • RoA
  • Therapeutic modality
  • Geographical coverage

Recruitment Strategies

  • Recruitment status
  • Gender
  • Age

Key Companies

  • Type of players
  • Company overview

Discontinued or Dormant Molecules

About Technavio

is a leading global technology research and advisory company. Their
research and analysis focuses on emerging market trends and provides
actionable insights to help businesses identify market opportunities and
develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio's report library consists
of more than 10,000 reports and counting, covering 800 technologies,
spanning across 50 countries. Their client base consists of enterprises
of all sizes, including more than 100 Fortune 500 companies. This
growing client base relies on Technavio's comprehensive coverage,
extensive research, and actionable market insights to identify
opportunities in existing and potential markets and assess their
competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team

View Comments and Join the Discussion!